290 related articles for article (PubMed ID: 26917015)
1. Immunodetection of human topoisomerase I-DNA covalent complexes.
Patel AG; Flatten KS; Peterson KL; Beito TG; Schneider PA; Perkins AL; Harki DA; Kaufmann SH
Nucleic Acids Res; 2016 Apr; 44(6):2816-26. PubMed ID: 26917015
[TBL] [Abstract][Full Text] [Related]
2. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
3. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.
Tomicic MT; Christmann M; Kaina B
Cancer Res; 2005 Oct; 65(19):8920-6. PubMed ID: 16204064
[TBL] [Abstract][Full Text] [Related]
4. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
[TBL] [Abstract][Full Text] [Related]
5. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
6. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
7. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
8. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2012; 7(11):e50427. PubMed ID: 23185622
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
10. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
López-Lázaro M; Willmore E; Austin CA
Mutat Res; 2010 Feb; 696(1):41-7. PubMed ID: 20025993
[TBL] [Abstract][Full Text] [Related]
11. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Jobson A; Gilroy KL; Curtis H; Padget K; Austin CA
J Nat Prod; 2007 Dec; 70(12):1884-8. PubMed ID: 18076140
[TBL] [Abstract][Full Text] [Related]
12. Replicative helicases can translocate through abasic site-induced covalent topoisomerase IV-DNA complexes.
Shea ME; Hiasa H
Nucleic Acids Res; 2001 Feb; 29(3):614-21. PubMed ID: 11160881
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of camptothecin.
Liu LF; Desai SD; Li TK; Mao Y; Sun M; Sim SP
Ann N Y Acad Sci; 2000; 922():1-10. PubMed ID: 11193884
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
15. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
[TBL] [Abstract][Full Text] [Related]
16. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
[TBL] [Abstract][Full Text] [Related]
18. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
19. 3-Arylisoquinolines as novel topoisomerase I inhibitors.
Khadka DB; Cho WJ
Bioorg Med Chem; 2011 Jan; 19(2):724-34. PubMed ID: 21095131
[TBL] [Abstract][Full Text] [Related]
20. Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Elliott SL; Austin CA
Int J Cancer; 2008 Nov; 123(9):2217-21. PubMed ID: 18712718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
